11月6日，运达股份盘中上涨2.01%，截至10:36，报18.79元/股，成交1.26亿元，换手率0.98%，总市值 147.85亿元。 资金流向方面，主力资金净流入413.15万元，特大单买入268.04万元，占比2.13%，卖出101.58万元，占 比0.81%；大单买入1792.92万元，占比14.21%，卖出1546.22万元，占比12.26%。 分红方面，运达股份A股上市后累计派现2.81亿元。近三年，累计派现1.53亿元。 机构持仓方面，截止2025年9月30日，运达股份十大流通股东中，香港中央结算有限公司位居第二大流 通股东，持股902.48万股，相比上期减少179.86万股。华夏复兴混合A（000031）位居第六大流通股 东，持股549.47万股，持股数量较上期不变。博时恒乐债券A（014846）位居第七大流通股东，持股 454.91万股，为新进股东。南方中证1000ETF（512100）位居第九大流通股东，持股431.50万股，相比 上期减少4.29万股。 资料显示，运达能源科技集团股份有限公司位于浙江省杭州市西湖国际科技大厦A座18F，成立日期 2001年11月30日，上市日期2019年 ...

资料显示，浙江维康药业股份有限公司位于浙江省丽水经济开发区遂松路2号，成立日期2000年3月31 日，上市日期2020年8月24日，公司主营业务涉及现代中药及西药的研发、生产和销售。主营业务收入 构成为：中西成药97.16%，其他(补充)2.84%。 11月6日，维康药业（维权）盘中下跌2.13%，截至09:54，报26.20元/股，成交3083.24万元，换手率 0.81%，总市值37.94亿元。 资金流向方面，主力资金净流入24.80万元，特大单买入0.00元，占比0.00%，卖出127.91万元，占比 4.15%；大单买入309.39万元，占比10.03%，卖出156.68万元，占比5.08%。 维康药业今年以来股价涨75.45%，近5个交易日涨14.21%，近20日涨17.59%，近60日涨9.49%。 今年以来维康药业已经2次登上龙虎榜，最近一次登上龙虎榜为7月21日。 维康药业所属申万行业为：医药生物-中药Ⅱ-中药Ⅲ。所属概念板块包括：小盘、民营医院、抗流感、 医药电商、送转填权等。 截至9月30日，维康药业股东户数1.06万，较上期增加7.09%；人均流通股13605股，较上期减少6.62%。 ...

金三江今年以来股价涨2.63%，近5个交易日涨7.33%，近20日涨9.98%，近60日涨1.30%。 11月5日，金三江盘中上涨2.05%，截至10:17，报12.45元/股，成交2212.11万元，换手率0.87%，总市值 28.78亿元。 资金流向方面，主力资金净流出71.38万元，大单买入246.78万元，占比11.16%，卖出318.15万元，占比 14.38%。 机构持仓方面，截止2025年9月30日，金三江十大流通股东中，诺安多策略混合A（320016）位居第五 大流通股东，持股137.57万股，为新进股东。中信保诚多策略混合(LOF)A（165531）、国泰海通君得 鑫2年持有混合A（952009）退出十大流通股东之列。 资料显示，金三江(肇庆)硅材料股份有限公司位于广东省肇庆高新区创业路15号，成立日期2003年12月 3日，上市日期2021年9月13日，公司主营业务涉及沉淀法二氧化硅的研发、生产和销售。主营业务收入 构成为：二氧化硅99.53%，其他0.47%。 责任编辑：小浪快报 金三江所属申万行业为：基础化工-化学制品-其他化学制品。所属概念板块包括：小盘、微盘股、气凝 胶、融资融券、 ...

11月4日，新宙邦盘中下跌2.00%，截至13:50，报49.88元/股，成交7.20亿元，换手率2.62%，总市值 372.99亿元。 资金流向方面，主力资金净流出1756.65万元，特大单买入2009.51万元，占比2.79%，卖出4227.64万 元，占比5.88%；大单买入1.76亿元，占比24.41%，卖出1.71亿元，占比23.77%。 新宙邦今年以来股价涨34.65%，近5个交易日涨2.63%，近20日跌0.54%，近60日涨46.88%。 资料显示，深圳新宙邦科技股份有限公司位于广东省深圳市坪山区昌业路新宙邦科技大厦，成立日期 2002年2月19日，上市日期2010年1月8日，公司主营业务涉及新型电子化学品及功能材料的研发、生 产、销售和服务。主营业务收入构成为：电池化学品66.43%，有机氟化学品17.03%，电子信息化学品 16.03%，其他(补充)0.50%。 新宙邦所属申万行业为：电力设备-电池-电池化学品。所属概念板块包括：固态电池、宁德时代概念、 送转填权、特斯拉、4680电池等。 截至9月30日，新宙邦股东户数4.56万，较上期增加19.44%；人均流通股11840股，较上期减少 ...

Core Viewpoint - The company, Fuzhi Environmental Protection, is a leading enterprise in the field of sludge dewatering, drying, and waste gas purification technology in China, with a comprehensive service capability across the entire industry chain [1] Group 1: Business Performance - For Q3 2025, Fuzhi Environmental Protection reported revenue of 201 million yuan, ranking 45th among 51 companies in the industry, significantly lower than the top performer, Shougang Environmental Protection, which had 13.453 billion yuan, and the industry average of 1.671 billion yuan [2] - The net profit for the same period was 1.4683 million yuan, placing the company 41st in the industry, again far behind the leading companies and below the industry average of 230 million yuan [2] Group 2: Financial Ratios - As of Q3 2025, the company's debt-to-asset ratio was 21.32%, an increase from 13.54% year-on-year, but still significantly lower than the industry average of 49.82%, indicating good debt repayment capability [3] - The gross profit margin for Q3 2025 was 25.61%, down from 30.06% year-on-year and below the industry average of 32.13%, suggesting a need for improvement in profitability [3] Group 3: Executive Compensation - The chairman, Huang Wenjun, received a salary of 1.7 million yuan in 2024, a decrease of 540,000 yuan from 2023 [4] - The general manager, Qu Xianwei, had a salary of 1.3 million yuan in 2024, an increase of 20,000 yuan from the previous year [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 49.32% to 6,437, while the average number of circulating A-shares held per account decreased by 33.03% to 23,000 [5]

Core Insights - The company, Weikang Pharmaceutical, was established on March 31, 2000, and went public on August 24, 2020, on the Shenzhen Stock Exchange, focusing on modern Chinese medicine and Western medicine research, production, and sales [1] Financial Performance - For Q3 2025, Weikang Pharmaceutical reported revenue of 151 million, ranking 67th among 69 companies in the industry, significantly lower than the top performer, Baiyunshan, with 61.606 billion, and Yunnan Baiyao at 30.654 billion, as well as below the industry average of 375.5 million and median of 146.2 million [2] - The net profit for the same period was -124 million, placing the company 65th in the industry, far behind Yunnan Baiyao's 4.789 billion and Baiyunshan's 3.398 billion, and also below the industry average of 447 million and median of 83.677 million [2] Financial Ratios - As of Q3 2025, Weikang Pharmaceutical's debt-to-asset ratio was 30.80%, an increase from 25.67% year-on-year, but still below the industry average of 32.81% [3] - The gross profit margin for Q3 2025 was 15.34%, a significant decline from 47.39% year-on-year, and also lower than the industry average of 52.44% [3] Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 7.09% to 10,600, while the average number of circulating A-shares held per shareholder decreased by 6.62% to 13,600 [5] Management Compensation - The chairman and general manager, Liu Yang, has a salary of 514,000 for the year 2024 [4]

Core Viewpoint - The company, Beijing Baipusais Biotechnology Co., Ltd., is experiencing growth in its stock performance and revenue, driven by advancements in cell immunotherapy, recombinant proteins, and its recognition as a "specialized, refined, distinctive, and innovative" enterprise [1][3][9]. Group 1: Company Performance - On October 31, the company's stock rose by 4.25%, with a trading volume of 177 million yuan and a market capitalization of 10.872 billion yuan [1]. - For the first nine months of 2025, the company achieved a revenue of 613 million yuan, representing a year-on-year growth of 32.26%, and a net profit attributable to shareholders of 132 million yuan, up 58.61% year-on-year [9]. - The company has distributed a total of 432 million yuan in dividends since its A-share listing, with 312 million yuan in the last three years [10]. Group 2: Product Development and Market Position - The company has launched a specific antibody targeting the CD19 antigen in CAR-T cell therapy, enhancing detection methods and expanding its product offerings in cell and gene therapy [2]. - It has developed high-quality recombinant proteins for various disease targets, supporting the research and production needs of biopharmaceuticals [2]. - The company is actively developing products related to monkeypox virus, including recombinant proteins and test kits, to aid in vaccine and therapeutic drug development [2]. Group 3: Industry Recognition and Financial Impact - The company has been recognized as a national-level "specialized, refined, distinctive, and innovative" small giant enterprise, which enhances its competitiveness and stability within the industry [3]. - As of the 2024 annual report, overseas revenue accounted for 66.46% of total revenue, benefiting from the depreciation of the yuan [4]. - The company operates in the pharmaceutical and biotechnology sector, specifically in the bioproducts category, and is involved in various concept sectors including financing, artificial intelligence, and mid-cap stocks [9].

Core Viewpoint - Chengda Pharmaceutical is a leading domestic pharmaceutical company focusing on key pharmaceutical intermediates CDMO services and L-carnitine series products, with strong R&D capabilities [1] Group 1: Business Performance - In Q3 2025, Chengda Pharmaceutical reported revenue of 285 million yuan, ranking 26th out of 29 in the industry, significantly lower than the top company WuXi AppTec at 32.857 billion yuan and second-ranked Kanglong Chemical at 10.086 billion yuan [2] - The net profit for Q3 2025 was 16.7931 million yuan, ranking 22nd out of 29, with a notable gap compared to WuXi AppTec's 12.206 billion yuan and Tigermed's 1.092 billion yuan [2] Group 2: Financial Ratios - Chengda Pharmaceutical's debt-to-asset ratio in Q3 2025 was 9.98%, up from 6.78% year-on-year, significantly lower than the industry average of 22.79%, indicating strong solvency [3] - The gross profit margin for Q3 2025 was 45.39%, an increase from 43.54% year-on-year, surpassing the industry average of 37.70%, reflecting strong profitability [3] Group 3: Executive Compensation - The chairman, Ge Jianli, received a salary of 602,700 yuan in 2024, a decrease of 374,200 yuan from 2023 [4] - The general manager, Lu Gang, earned 668,800 yuan in 2024, down 223,900 yuan from the previous year [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 8.58% to 12,700, while the average number of circulating A-shares held per account increased by 36.16% to 8,577.86 [5]

Core Viewpoint - Yunda Co., Ltd. has experienced a decline in stock price recently, with a year-to-date increase of 41.05% and a notable drop in net profit despite revenue growth [1][2]. Financial Performance - For the period from January to September 2025, Yunda Co., Ltd. achieved a revenue of 18.486 billion yuan, representing a year-on-year growth of 32.72% [2]. - The net profit attributable to shareholders was 251 million yuan, showing a decrease of 5.76% compared to the previous year [2]. Stock Market Activity - As of October 31, the stock price of Yunda Co., Ltd. was 18.59 yuan per share, with a market capitalization of 14.627 billion yuan [1]. - The stock has seen a trading volume of 270 million yuan and a turnover rate of 2.04% on the same day [1]. - The main funds experienced a net outflow of 39.85 million yuan, with significant selling pressure observed [1]. Shareholder Information - As of September 30, the number of shareholders decreased by 13.08% to 33,400, while the average circulating shares per person increased by 15.09% to 20,891 shares [2]. - The company has distributed a total of 281 million yuan in dividends since its A-share listing, with 153 million yuan in the last three years [3]. Business Overview - Yunda Co., Ltd. specializes in the research, production, and sales of large wind turbine generators, with wind power generation accounting for 87.54% of its main business revenue [1]. - The company is categorized under the power equipment industry, specifically in wind power equipment [1].

Core Insights - Kanglong Chemical experienced a stock price decline of 2.03% on October 30, trading at 33.36 CNY per share with a market capitalization of 59.32 billion CNY [1] - The company reported a year-to-date stock price increase of 30.82%, with a 6.11% rise over the last five trading days [1][2] Financial Performance - For the period from January to September 2025, Kanglong Chemical achieved a revenue of 10.09 billion CNY, reflecting a year-on-year growth of 14.38%, while the net profit attributable to shareholders decreased by 19.76% to 1.14 billion CNY [2] - Cumulative cash dividends since the company's A-share listing amount to 1.79 billion CNY, with 1.00 billion CNY distributed over the past three years [3] Shareholder Structure - As of September 30, 2025, the number of shareholders decreased by 1.62% to 86,500, with an average of 0 circulating shares per person [2] - Notable institutional shareholders include China Europe Medical Health Mixed Fund, which increased its holdings by 8.96 million shares, and Hong Kong Central Clearing Limited, which raised its stake by 1.02 million shares [3]